- Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, Breast Cancer, adj. cycle 2-4 PID 1168 V1.2 (2024-10-11)
V1.2:
Inserted a 60-minute observation period after administration of Pertuzumab
V1.1:
Cato test done.
Revision of allergy prophylaxis according to the summary of product characteristics, change of H2 antagonist for Paclitaxel from Ranitidine to Cimetidine according to DGHO recommendations 10/2019.
V1.0:
Cato test done.
V0.1:
This protocol serves as adjuvant therapy after EC/AC.
Duration according to the summary of product characteristics.
- Pertuzumab 600 / Trastuzumab 600, Breast Ca, adjuvant, 5-18 PID 1755 V1.2 (2024-10-11)
V1.2
Technische Korrektur der Anwendungszeiten
V1.1:
Substanzen zusammengefasst (Pertuzumab/Trastuzumab)
V1.0:
Cato Test erfolgt.
V0.1:
Laufzeiten nach Fachinformation.
- Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Breast Cancer, neoadjuvant, cycle 1 or cycle 4 PID 589 V1.2 (2024-10-09)
V1.2:
Inserted a 60-minute observation period after administration of Pertuzumab
V1.1:
Correction to title when protocol is incorporated into protocol sequences.
V1.0:
Cato test done.
V0.1:
Neosphere: Run times according to the summary of product characteristics of Pertuzumab. Sequence of substances in analogy to palliative therapy (Cleopatra study).
Tryphaena Arm B: This protocol follows Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, neoadjuvant, C1-3 (PID 1357) and is used for top-up dosing. Subsequently, 2 cycles of PERT420/TRAS6/DOCE75, Breast Ca, neoadjuvant, C2-4 or 4-6 or 5-6 (PID750) are used.
Maintenance therapy with Trastuzumab 6, Breast Cancer (HER2+) cycle 2+ will also be continued.
- Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Breast Cancer, neoadjuvant, cycle 2-4, 4-6, or 5-6 PID 750 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
Neosphere: This protocol is followed by adjuvant therapy with the protocol Fluorouracil 600 / Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, adjuvant, and maintenance therapy with TRAS6, Breast Ca, maint., adj, C2+ (PID1474).
Tryphaena Arm A: This protocol follows Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600 / Trastuzumab 6 / Pertuzumab 420, Breast Cancer, neoadjuvant, Cycle 2-3 (PID1468). Maintenance therapy with TRAS6, Breast Ca, maint., adj., C2+ (PID1474) is also offered.
Tryphaena Arm B: This protocol follows Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, neoadjuvant, C1-3 (PID589). Maintenance therapy with TRAS6, Breast Ca, maint., adj., C2+ (PID1474) is also recommended.
V0.1:
Duration according to the summary of product characteristics of Pertuzumab. Sequence of substances in analogy to palliative therapy (Cleopatra study).
- Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Breast Cancer, adjuvant, cycle 1 PID 1165 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
This protocol serves as adjuvant therapy after EC/AC.
Duration according to the summary of product characteristics of Pertuzumab. Sequence of substances in analogy to palliative therapy (Cleopatra study).
- Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Breast Cancer, adjuvant, cycle 2-4 PID 1166 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
This protocol serves as adjuvant therapy after EC/AC.
Duration according to the summary of product characteristics of Pertuzumab. Sequence of substances in analogy to palliative therapy (Cleopatra study).
- Pertuzumab 840 / Trastuzumab 8 / Paclitaxel 80, Breast Cancer, adj. cycle 1 PID 1167 V1.2 (2024-10-09)
V1.2:
Inserted a 60-minute observation period after administration of Pertuzumab
V1.1:
Cato test done.
Revision of allergy prophylaxis according to the summary of product characteristics, change of H2 antagonist for Paclitaxel from Ranitidine to Cimetidine according to DGHO recommendations 10/2019.
V1.0:
Cato test done.
V0.1:
This protocol serves as adjuvant therapy after EC/AC.
Duration according to the summary of product characteristics.
- Pertuzumab 840 / Trastuzumab 8 / Nab-Paclitaxel 125, Breast Cancer, neoadj. cycle 1 PID 1355 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Running times according to summary of product characteristics
Runtimes according to the summary of product characteristics.
- Pertuzumab 420 / Trastuzumab 6 / Nab-Paclitaxel 125, Breast Cancer, neoadj. cycle 2-4 PID 1356 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Running times according to summary of product characteristics
Runtimes according to the summary of product characteristics.
- Pertuzumab 420 / Trastuzumab 6 / Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, neoadj., cycle 5-8 PID 1410 V1.1 (2024-10-09)
V1.1:
Protocol numbering changed.
Inserted a 60-minute observation period after administration of Pertuzumab
V1.0:
Cato test done
V0.1:
Running times according to summary of product characteristics
- Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75 / Carboplatin 6, Breast Cancer, neoadjuvant, cycle 2-6 PID 1470 V2.1 (2024-10-09)
V2.1:
Duration of Pertuzumab adjusted. A 60-minute observation period inserted after administration of Pertuzumab
V2.0:
Cato test done.
Addition of Carboplatin
V1.0:
Cato test done.
V0.1:
This protocol is followed by maintenance therapy with TRAS6, Breast Ca, maint., adj, C2+ (PID1474)
This protocol contains arm C.
Duration according to the summary of product characteristics of Pertuzumab. Sequence of substances in analogy to palliative therapy (Cleopatra study).
- Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, Cycle 2+ PID 1497 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Pertuzumab 600 / Trastuzumab 600 / Nab-Paclitaxel 125, Breast Cancer, Cycle 2+ PID 1757 V1.2 (2024-10-09)
V1.2:
Substances combined (Pertuzumab/Trastuzumab)
V1.1:
Dosing Nab-Paclitaxel adjusted analogous to GBG 69-GeparSepto study.
V1.0:
Cato test done.
V0.1:
Run times according to the summary of product characteristics.
- Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80 / Carboplatin 6, Breast Carcinoma, neoadjuvant, cycle 2-9 PID 2122 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1
Dosing according to the primary literature, duration according to the summary of product characteristics
- Pertuzumab 840 / Trastuzumab 8 / Paclitaxel 80, Breast Cancer, neoadjuvant, cycle 1 PID 2431 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Dosing according to the study protocol, durations according to the summary of product characteristics.
- Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, Breast Cancer, neoadjuvant, cycle 2-4 PID 2432 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Dosing according to the study protocol, durations according to the summary of product characteristics.
- Pertuzumab 840 / Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Neoadjuvant, Cycle 1 PID 2433 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, Neoadjuvant, Cycle 2-4 PID 2434 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Pertuzumab 840 / Trastuzumab 8 / Tamoxifen 20, Breast Cancer, neoadjuvant, cycle 1 PID 2440 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Pertuzumab 420 / Trastuzumab 6 / Tamoxifen 20, Breast Cancer, Neoadjuvant, Cycle 2-4 PID 2441 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, adjuvant, Cycle 2-9 PID 2442 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Pertuzumab 420 / Trastuzumab 6 / Tamoxifen 20, Breast Cancer, adjuvant, cycle 2-9 PID 2443 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Pertuzumab 840 / Trastuzumab 8 / Tamoxifen 20, Breast Cancer, adjuvant, cycle 1 PID 2450 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Pertuzumab 840 / Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Adjuvant, Cycle 1 PID 2451 V1.1 (2024-10-09)
V1.1:
A 60-minute observation period inserted after administration of Pertuzumab
V1.0:
Cato test done.
V0.1:
Sequence and durations according to the summary of product characteristics.
- Nab-Paclitaxel 125 / Trastuzumab 2, Breast Cancer, Cycle 2+ PID 428 V1.1 (2024-10-08)
V1.1:
Protocol name adapted to the current nomenclature
V1.0:
Cato test done.
Runtime according to primary literature.
Use this protocol from C2, for the 1st cycle use protocol NPAC125 p.w./TRAS, Breast Ca C1 (TRAS loading dose) once.
- Pertuzumab 1200 / Trastuzumab 600 / Docetaxel 100, Breast Ca, adjuvant, cycle 1 PID 1751 V1.1 (2024-10-08)
V1.1:
Protocol name changed according to current standard
V1.0:
Cato test done.
V0.1:
Duration of chemotherapy according to Sparano et al 2008, antibody - according to primary literature.
Application of this protocol after 4 cycles of AC, see AC(60/600) x 4 followed by DOCE100 x 4, Breast Ca, adj., A, PID599
- Pertuzumab 600 / Trastuzumab 600 / Docetaxel 100, Breast Ca, adjuvant, cycle 2-4 PID 1752 V1.1 (2024-10-08)
V1.1:
Protocol name changed according to current standard
V1.0:
Cato test done.
V0.1:
Duration of chemotherapy according to Sparano et al 2008, antibodies - according to primary literature.
- Pertuzumab 1200 / Trastuzumab 600 / Paclitaxel 80, Breast Ca, adjuvant, cycle 1 PID 1753 V2.1 (2024-10-08)
V2.1:
Title adapted to the current nomenclature
V2.0
Number of cycles corrected
V1.0:
Cato test done.
V0.1:
Run times according to summary of product characteristics.
Application of this protocol after 4 cycles of AC, see dose-dense AC x 4 followed by PACL x 4, Breast Ca, adjuvant, A, PID402
- Pertuzumab 600 / Trastuzumab 600 / Paclitaxel 80, Breast Ca, adjuvant, cycle 2-4 PID 1754 V1.1 (2024-10-08)
V1.1:
Title adapted to the current nomenclature
V1.0:
Cato test done.
V0.1:
Terms according to summary of product characteristics.
- Pertuzumab 1200 / Trastuzumab 600 / Nab-Paclitaxel 125, Breast Cancer, Cycle 1 PID 1756 V1.1 (2024-10-08)
V1.1:
Substances combined (Pertuzumab/Trastuzumab)
V1.0:
Cato test done.
V0.1:
Duration according to summary of product characteristics. Dosing Nab-Paclitaxel analogous to GBG 69-GeparSepto study.
Duration according to the summary of product characteristics.
- Pertuzumab 1200 / Trastuzumab 600 / Paclitaxel 80, Breast Cancer, Cycle 1 PID 1758 V1.1 (2024-10-08)
V1.1:
Substances combined (Pertuzumab/Trastuzumab)
V1.0:
Cato test done.
V0.1
Term antibody according to primary literature, Paclitaxel according to Smyth et al.
- Pertuzumab 600 / Trastuzumab 600 / Paclitaxel 80, Breast Cancer, Cycle 2+ PID 1759 V1.1 (2024-10-08)
V1.1:
Substances combined (Pertuzumab/Trastuzumab)
V1.0:
Cato test done.
V0.1
Term antibody according to primary literature, Paclitaxel according to Smyth et al.
- Pertuzumab 600 / Trastuzumab 600, Breast Cancer PID 1760 V1.1 (2024-10-08)
V1.1:
Substances combined (Pertuzumab/Trastuzumab)
V1.0:
Cato test done.
V0.1
Duration according to primary literature.
